Key Developments: Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

105.10USD
11 Jul 2014
Price Change (% chg)

$-0.70 (-0.66%)
Prev Close
$105.80
Open
$106.00
Day's High
$106.00
Day's Low
$104.86
Volume
1,283,268
Avg. Vol
1,926,345
52-wk High
$106.74
52-wk Low
$85.50

Search Stocks

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson announces quarterly dividend
Thursday, 2 Jan 2014 08:30am EST 

Johnson & Johnson:Says it has declared a cash dividend for the first quarter of 2014 of $0.66 per share on the company's common stock.Says the dividend is payable on Mar. 11 to shareholders of record at the close of business on Feb. 25.Says the ex-dividend date is Feb. 21.  Full Article

EU regulators fine Johnson & Johnson, Novartis AG 16 mln euros for generic drug deal - Reuters
Tuesday, 10 Dec 2013 09:00am EST 

Johnson & Johnson and Novartis AG:European Union antitrust regulators fined Johnson & Johnson .N and Novartis AG a total of 16 million euros ($21.95 million) on Dec. 10 for blocking the sale of a generic painkiller in the Dutch market - Reuters.The European Commission said in a statement that the deal between the two companies meant patients did not have access to the cheaper generic version of fentanyl for 17 months starting from July 2005.Johnson & Johnson and its Dutch unit, Janssen-Cilag, were fined 10.8 million euros while Novartis and its Dutch subsidiary, Sandoz, were fined 5.5 million euros.  Full Article

Johnson & Johnson's Unit To Pay $2.5 Billion In U.S. Hip Implant Settlement-Reuters
Tuesday, 19 Nov 2013 05:18pm EST 

Reuters reported that a unit of Johnson & Johnson has agreed to pay an estimated $2.5 billion to settle thousands of lawsuits from individuals allegedly injured by the Company‚Äôs artificial hip implants. The settlement would compensate an estimated 8,000 patients who underwent surgery to replace their hip implants, according to a statement from Johnson & Johnson unit Depuy Orthopaedics Inc and lawyers for the plaintiffs.  Full Article

Johnson & Johnson To Reach $4 Billion Deal On Hip Implant Lawsuits - Reuters
Tuesday, 12 Nov 2013 04:47pm EST 

Reuters reported that Johnson & Johnson will pay more than $4 billion to settle thousands of lawsuits over its recalled defective hip implants. The deal will resolve more than 7,500 lawsuits in federal and state courts by patients who have already had the defective devices removed, the report said.  Full Article

Danaher Corp, Blackstone Group LP Team Up To Bid For Johnson & Johnson's Diagnostics Unit-Reuters
Thursday, 7 Nov 2013 05:33pm EST 

Reuters reported that Danaher Corp has teamed up with Blackstone Group LP to bid for Johnson & Johnson's diagnostics unit, which makes blood screening equipment and laboratory blood tests and could fetch more than $4 billion. Blackstone, declined to comment. Representatives for J&J, Danaher did not immediately respond to requests for comment.  Full Article

Johnson & Johnson To Pay $2.2 Billion To End U.S. Marketing Probes-Reuters
Monday, 4 Nov 2013 10:30am EST 

Reuters reported that Johnson & Johnson will pay $2.2 billion to the U.S. government to end multiple investigations into kickbacks to pharmacists and the marketing of pharmaceuticals for off-label uses. The settlement with the Company and its subsidiaries covers the marketing of schizophrenia treatment Risperdal and of heart drug Natrecor.  Full Article

FDA Advisory Panel Backs Approval Of Johnson & Johnson's Hepatitis C Drug-Reuters
Thursday, 24 Oct 2013 04:36pm EDT 

Reuters reported that an advisory committee of the U.S. Food and Drug Administration voted unanimously to approve Johnson & Johnson's hepatitis C drug. The panel voted 19-0 in favor of the drug, simeprevir, which was tested in combination with standard hepatitis C drugs, peginterferon-alpha and ribavirin. The drug is being developed by J&J unit Janssen Research & Development LLC. It is being tested in adults who failed previous interferon-based therapy or had not received medication at all. The FDA usually follows the recommendation of the advisory panel, although it is not obligated to do so. Hepatitis C, an infection of the liver transmitted through the blood, kills more than 15,000 Americans each year, mostly from hepatitis C-related illnesses such as cirrhosis and liver cancer.  Full Article

Johnson & Johnson's Hepatitis C Drug Gets Positive FDA Review-Reuters
Tuesday, 22 Oct 2013 11:42am EDT 

Reuters reported that a new hepatitis C drug made by Johnson & Johnson showed an acceptable safety profile in clinical trials, reviewers for the U.S. Food and Drug Administration said on October 22, 2013. The drug, simeprevir, was tested in combination with standard hepatitis C drugs, peginterferon-alpha and ribavirin, in adult patients who had failed previous interferon-based therapy or had not received medication at all. The safety signal identified in the review of the drug involved rash and/or photosensitivity and the FDA reviewers said they plan to include a related warning in the drug's label. The reviewers said that the drug would be categorized as a Pregnancy Category C in labeling, which means that the potential benefits of the drug may warrant its use in pregnant women, even though animal trials showed the drug had some adverse effects on a fetus.  Full Article

Johnson & Johnson Announces Quarterly Dividend For Fourth Quarter
Thursday, 17 Oct 2013 11:16am EDT 

Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2013 of $0.66 per share on the Company's common stock. The dividend is payable on December 10, 2013 to shareholders of record at the close of business on November 26, 2013. The ex-dividend date is November 22, 2013.  Full Article

Johnson & Johnson Raises FY 2013 EPS Guidance
Tuesday, 15 Oct 2013 07:30am EDT 

Johnson & Johnson raised its fiscal 2013 earnings guidance to $5.44-$5.49 per share. The Company's guidance excludes the impact of special items. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $5.46 for fiscal 2013.  Full Article

Obama meets with CEOs of Goldman Sachs, others, on family issues

WASHINGTON - President Barack Obama met with Goldman Sachs Chief Executive Lloyd Blankfein, Johnson & Johnson chief Alex Gorsky and other business leaders on Monday to discuss ways to encourage companies to make their work places more family friendly.

Search Stocks